<Record>
<Term>Irbesartan</Term>
<SemanticType>Pharmacologic Substance</SemanticType>
<SemanticType>Organic Chemical</SemanticType>
<ParentTerm>Angiotensin II Receptor Antagonist</ParentTerm>
<ClassificationPath>Chemicals_and_Drugs_Kind/Drug, Food, Chemical or Biomedical Material/Pharmacologic Substance/Adjuvant/Cardiovascular Agent/Antihypertensive Agent/Angiotensin II Receptor Antagonist/Irbesartan</ClassificationPath>
<BroaderTerm>Chemicals_and_Drugs_Kind</BroaderTerm>
<BroaderTerm>Cardiovascular Agent</BroaderTerm>
<BroaderTerm>Irbesartan</BroaderTerm>
<BroaderTerm>Pharmacologic Substance</BroaderTerm>
<BroaderTerm>Adjuvant</BroaderTerm>
<BroaderTerm>Angiotensin II Receptor Antagonist</BroaderTerm>
<BroaderTerm>Antihypertensive Agent</BroaderTerm>
<BroaderTerm>Drug, Food, Chemical or Biomedical Material</BroaderTerm>
<Synonym>Irbesartan</Synonym>
<Synonym>Avapro</Synonym>
<Synonym>IRBESARTAN</Synonym>
<Description>A nonpeptide angiotensin II antagonist with antihypertensive activity. Irbesartan selectively and competitively blocks the binding of angiotensin II to the angiotensin I receptor. Angiotensin II stimulates aldosterone synthesis and secretion by adrenal cortex, which decreases the excretion of sodium and increases the excretion of potassium. Angiotensin II also acts as a vasoconstrictor in vascular smooth muscle. (NCI05)</Description>
<Source>FDA Registry</Source>
<Source>NCI Thesaurus</Source>
</Record>
